Scholar Rock Holding Corporation

Equities

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
14.53 ^USD	+4.08%		+4.91%	-22.71%

Mar. 28	Scholar Rock Shares Rise After Raymond James Initiates Coverage	MT
Mar. 28	Raymond James Initiates Scholar Rock With Strong Buy Rating, $30 Price Target	MT

Scholar Rock Holding Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 07, 2023 at 07:31 am EST

Scholar Rock Holding Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 42.36 million compared to USD 43.3 million a year ago.
For the nine months, net loss was USD 119.66 million compared to USD 95.25 million a year ago.

Latest news about Scholar Rock Holding Corporation

Scholar Rock Shares Rise After Raymond James Initiates Coverage	Mar. 28	MT
Raymond James Initiates Scholar Rock With Strong Buy Rating, $30 Price Target	Mar. 28	MT
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
North American Morning Briefing : Investors -2-	Mar. 18	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
Scholar Rock Announces Management Appointments	Feb. 15	CI
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management	Feb. 06	CI
Scholar Rock Says FDA Clears Application for Trial of Obesity Treatment Apitegromab	Jan. 23	DJ
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity	Jan. 23	CI
Transcript : Scholar Rock Holding Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 01:30 PM	Jan. 09
Scholar Rock Holding Corporation(NasdaqGS:SRRK) added to S&P Biotechnology Select Industry Index	Dec. 18	CI
Scholar Rock Holding Insider Sold Shares Worth $448,444, According to a Recent SEC Filing	Dec. 15	MT
Certain Common Warrants of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	Dec. 10	CI
Certain Restricted Stock Units of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	Dec. 10	CI
Certain Stock Options of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	Dec. 10	CI
Certain Common Stock of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	Dec. 10	CI
Certain Pre-funded Warrants of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	Dec. 10	CI
Scholar Rock Holding Insider Sold Shares Worth $436,820, According to a Recent SEC Filing	Dec. 08	MT
Transcript : Scholar Rock Holding Corporation, Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Scholar Rock Holding Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Scholar Rock Holding Insider Sold Shares Worth $438,039, According to a Recent SEC Filing	Nov. 06	MT
Scholar Rock's Experimental Drug Shows Anti-Tumor Activity in Early-Stage Trial	Nov. 03	MT
Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability	Nov. 03	CI
North American Morning Briefing : Nasdaq Futures -2-	23-10-26	DJ

Chart Scholar Rock Holding Corporation

Duration

Period

More charts

Company Profile

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of medicines for the treatment of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. The Company's product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGF?1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. The Company is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGF?1 in the context of fibrotic extracellular matrix and that avoid perturbing TGF?1 presented by cells of the immune system.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.53 USD

Average target price

26.25 USD

Spread / Average Target

+80.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SCHOLAR ROCK HOLDING CORPORATION	-22.71%	1.16B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+0.73%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.96%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs